These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21342593)

  • 1. [Patient safety in clinical intervention research].
    Brekelmans CT; Kenter MJ; Bouter LM; Koëter GH
    Ned Tijdschr Geneeskd; 2011; 155():A2359. PubMed ID: 21342593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the Data and Safety Monitoring Committee (DSMC).
    Wilhelmsen L
    Stat Med; 2002 Oct; 21(19):2823-9. PubMed ID: 12325098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethics committees and achievement of good clinical practice.
    Glasa J; Holomán J; Klepanec J; Soltés L
    Therapie; 1996; 51(4):369-72. PubMed ID: 8953810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
    Brosteanu O; Houben P; Ihrig K; Ohmann C; Paulus U; Pfistner B; Schwarz G; Strenge-Hesse A; Zettelmeyer U
    Clin Trials; 2009 Dec; 6(6):585-96. PubMed ID: 19897532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled clinical trials in drug research: permission versus notification.
    Deutsch E
    Health Law Can; 1989; 9(3):71-3. PubMed ID: 10313021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Unnecessary delays in ethical approval of multicentre clinical trials].
    Evers JL
    Ned Tijdschr Geneeskd; 2008 Sep; 152(38):2062-4. PubMed ID: 18837181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacy Department standard procedures for clinical trial development].
    Pérez Peiró C; Porta Oltra B; Cholvi Llovell M; Jiménez Torres NV
    Farm Hosp; 2004; 28(1):36-47. PubMed ID: 15012177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in Israel. Criteria for approval.
    Nir I
    Isr J Med Sci; 1983 May; 19(5):445-8. PubMed ID: 6862851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early stopping of clinical trials.
    Cuzick J; Howell A; Forbes J
    Breast Cancer Res; 2005; 7(5):181-3. PubMed ID: 16168134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
    Brun-Buisson C
    Med Sci (Paris); 2005 Feb; 21(2):187-9. PubMed ID: 15691491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.